



CHIMERIC THERAPEUTICS

THE ASX LEADER IN CELL THERAPY

THE CORE-NK PLATFORM

PHASE 1 CLINICAL DATA


MONDAY MARCH 7, 2022

ersonal use only

CORE-NK PLATFORM (CHM 0201)

Clinically Validated, **O**ff the Shelf, **R**obust, **E**nhanced, **N**atural **K**iller Cell Platform

- A universal, off the shelf, natural killer cell platform technology
- Developed by Dr. David Wald, a clinical scientist at Case Western Reserve University
- Specifically designed to overcome the hurdles often associated with NK cell development, including the ability to produce large numbers of highly active universal donor NK cells that maintain their activity once they're in the body.
- Chimeric exclusive option with a planned licensing and research collaboration with Case Western
- Platform enables near-term development Chimeric therapies for solid tumors and blood cancers



**David
WALD, MD, PhD**

Associate Professor, Department
of Pathology, School of Medicine
Member, Immune Oncology Program,
Case Comprehensive Cancer Center,
Associate Director for Basic Research, University
Hospitals, Wesley Center for Immunotherapy



CORE-NK Platform

Positive Phase 1A Clinical Data

COMPELLING EFFICACY IN BLOOD CANCERS

100% Disease Control Rate (DCR) achieved in blood cancer patients (n=3)

100+ day durability in 2 out of 3 patients

Durable Complete Response (CR) achieved with **15+** month ongoing response

PROMISING EFFICACY IN SOLID TUMORS

33% Disease Control Rate (DCR) achieved in solid tumor patients (n=6)

DEMONSTRATED SAFETY

Positive safety profile established with no Graft versus Host Disease (GvHD), Cytokine Release Syndrome or Dose Limiting Toxicities

ESTABLISHED EXPANSION AND PERSISTENCE

Proven robust expansion of universal donor NK cells

Demonstrated **4-week** persistence without exogenous cytokine support

CORE-NK PLATFORM

PHASE 1A TRIAL DESIGN

The trial was designed to establish the safety of CORE-NK universal donor NK cells while assessing cell expansion, persistence and anti-tumor activity.

PATIENT ELIGIBILITY

BLOOD CANCERS

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Myeloproliferative Syndromes
Non-Hodgkin Lymphoma
Hodgkin Lymphoma

SOLID TUMORS

Adenocarcinoma of the Rectum
Rhabdomyosarcoma
Soft Tissue Sarcoma
Ewing's Sarcoma
Colon Cancer

PRIMARY OBJECTIVE:

To demonstrate that escalating doses of the CORE-NK platform could be infused without inducing GvHD or other significant toxicities

SECONDARY OBJECTIVE:

To examine if the lymphocyte depleting regimen would prevent immediate rejection of the HLA-mismatched NK cell product allowing for demonstrable anti-tumor effect

Study Initiation: May 2018


Primary Study Completion: June 2021

CORE-NK PLATFORM

PHASE 1A TRIAL DESIGN


ersonal use only

PHASE 1 DOSE ESCALATION



Dosing:

9 patients : 3 Blood Cancers / 6 Solid Tumors



CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

SAFETY ESTABLISHED ACROSS ALL DOSE LEVELS

NO GRAFT VERSUS HOST
DISEASE (GVHD)

NO CYTOKINE RELEASE
SYNDROME (CRS)

NO DOSE LIMITING
TOXICITIES
(DLT'S)

All observed events were expected events attributable to the lymphocyte-depleting chemotherapy regimen.

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

5 OF 9 (56%) PATIENTS EXPERIENCED DISEASE STABILITY
INCLUDING ONE COMPLETE REMISSION

Cell Dose	10 x 10 ⁶ /kg			25 x 10 ⁶ /kg			50 x 10 ⁶ /kg		
Patient ID #	#1	#4	#5	#7	#8	#12	#13	#14	#15
Diagnosis	MDS/AML	Colorectal	Colorectal	Colorectal	High-Risk MDS, post-HCT relapse	Myeloid Sarcoma	Colon Cancer	Colon Cancer	Colon Cancer
Metastatic sites	N/A	multiple	lungs	multiple	N/A	N/A	Multiple	Lung	Liver, lungs
Response D28	Stable	Progression	Stable	Progression	Stable	Stable	Progression	Stable	Progression
Response D100	Progression	N/A	Stable	N/A	CRi	Stable	N/A	Progression	N/A

MDS=Myelodysplastic syndromes; AML=Acute myeloid leukemia; mCRC=Metastatic colorectal cancer; CRi=Complete Response with incomplete platelet recovery; SD=Stable Disease; PD=Progressive disease; DCR=Disease Control Rate; CRS=Cytokine release syndrome; GVHD=Graft vs. Host disease

1. Olegbeye et al, 2022; Transplantation & Cellular Therapy. doi.org/10.1016/j.jct.2022.02.008

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

100% DISEASE CONTROL IN PATIENTS WITH BLOOD CANCERS

Hematological Malignancies			
Cell Dose	10 x 10 ⁶ /kg	25 x 10 ⁶ /kg	25 x 10 ⁶ /kg
Patient ID #	#1	#8	#12
Diagnosis	MDS/AML	High-Risk MDS, post-HCT relapse	Myeloid Sarcoma
Response D28	Stable	Stable	Stable
Response D100	Progression	CRi	Stable

100%
DCR

66%
100-day durability of
response

1 CRi
With 15+ month
durability of remission

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS

COMPLETE RESPONSE IN HIGH RISK MDS

Case Study: Patient ID #8

Complete response with 15+ months ongoing remission

DIAGNOSIS:	High risk MDS with circulating blasts and high tumor burden
HISTORY:	Progressive disease with prior allogeneic transplant
RESPONSE:	Stable Disease at day 28, Complete Response by day 60
DURABILITY OF RESPONSE:	Sustained Complete Response at Day 100 Remains in remission 15+ months after receiving consolidation transplant
SAFETY:	No dose limiting toxicities, no cytokine release syndrome, no GvHD

CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS¹

DISEASE CONTROL IN HEAVILY PRE-TREATED METASTATIC COLORECTAL PATIENTS

Cell Dose
Patient ID #
Diagnosis
Metastatic sites
Response D28
Response D100

10 x 10 ⁶ /kg		25 x 10 ⁶ /kg	50 x 10 ⁶ /kg		
#4	#5	#7	#13	#14	#15
Colorectal	Colorectal	Colorectal	Colon	Colon	Colon
Multiple	Lungs	Multiple	Multiple	Lung	Multiple
Progression	Stable	Progression	Progression	Stable	Progression
N/A	Stable	N/A	N/A	Progression	N/A

33%
DCR

50%


100-day durability of response

1. Olegbeye et al, 2022; Transplantation & Cellular Therapy. doi.org/10.1016/j.jtct.2022.02.008


CORE-NK PLATFORM (CHM 0201)

DEMONSTRATED EXPANSION AND PERSISTENCE WITH UNIVERSAL DONOR NK CELLS


**Universal Donor
(non-HLA matched)
NK cells**



**Robust Expansion
Demonstrated
(up to 30,000-fold)**



**28 Day
Persistence
with no GvHD**



ersonal use only

CORE-NK PLATFORM PHASE 1 CLINICAL TRIAL: OVERCOMING THE CHALLENGES OF NK CELL DEVELOPMENT

THERAPEUTIC EFFECT IN SOLID TUMORS
AND BLOOD CANCERS

01

Established anti-tumor effect with responses in blood cancers and solid tumors past day 100 and a complete response in High-Risk MDS

ESTABLISHED SAFETY WITH UNIVERSAL
DONOR CELLS

02

Demonstrated lack of GvHD allows for donor simplification and delivery of a true universal therapy while enhancing “graft versus tumor” effect

28 DAY PERSISTENCE WITH HIGHER
LYMPHODEPLETION DOSE

03

Higher lymphodepleting dose prevents immediate host rejection for longer – up to 28 day – cell persistence

ROBUST EXPANSION:
MANUFACTURING SUCCESS

04

Successful generation of large quantities of CORE-NK cells from one donor, with one 21-day manufacturing run simplifies logistical feasibility and reduces costs

IDENTIFIED OPPORTUNITY TO
AMPLIFY THERAPEUTIC EFFECT


05

Opportunity to enhance anti-tumor activity by increasing the CORE-NK cell dose, providing exogenous cytokine support and promoting tumor bed infiltration

CORE-NK PLATFORM (CHM 0201)

ACCELERATING MULTIPLE DEVELOPMENT PATHS

ersonal use only



1.

CORE-NK Combination Therapy

Rapid development in combination therapy

2.

Next Generation CORE-NK Platform

Further enhancement with next generation technologies

3.

CAR-NK Products

Fast-forward development of CAR NK products using our CLTX and CDH17 chimeric antigen receptors

4.

Leverage the CORE-NK Platform

Identify collaborations or licensing opportunities to further expand the utilization of the CORE-NK platform



THE ASX LEADER IN
CELL THERAPY AND
AN EMERGING
GLOBAL CELL
THERAPY
COMPANY

- ✓ **Innovative & Diversified Portfolio**
7 novel individualized (autologous) T cell and off the shelf (allogeneic) NK cell therapies

- ✓ **Extensive Clinical Development**
4 planned clinical programs in 2022 and 8 planned clinical programs by 2023

- ✓ **World Renowned Partners**
Research collaborations with world renowned cell therapy centers and scientists

- ✓ **Broad Therapeutic Focus**
Development 10+ types of blood cancers and solid tumors for extensive commercial opportunity

- ✓ **Early Positive Signals in Multiple Trials**
Initial positive phase 1 clinical data in GBM and with the CORE-NK platform

- ✓ **Industry Leading Experience**
Internal team of experts in successful cell therapy development and commercialization



CHIMERIC
THERAPEUTICS

CONTACT INFORMATION

Jennifer Chow

Chief Executive Officer
and Managing Director
Cell: +1 908-723-8387
jchow@chimerictherapeutics.com

Paul Hopper

Executive Chairman
Cell: +61 406 671 515
paulhopper@lifescienceportfolio.com

ersonal use only